
Jim Beam column:Ivermectin can cause problems
Louisiana state Sen. Mike Fesi, R-Houma, is sponsoring legislation that will make it easier for people to purchase ivermectin, a questionable drug.(Photo courtesy of Facebook).
Louisiana's Republican public officials haven't stopped complaining about former Democratic Gov. John Bel Edwards' handling of the COVID pandemic since he left office. Edwards' actions actually saved many lives, but that has been conveniently overlooked in GOP efforts to promote some of their own weird plans.
State Sen. Michael 'Big Mike' Fesi of Houma, for example, is sponsoring Senate Bill 19 that would authorize pharmacists in Louisiana to dispense the ivermectin drug without requiring a prescription from a patient's physician. The Advocate reported that ivermectin is a powerful anti-parasitic drug approved to treat specific infections in humans and was widely used in animals, particularly horses and livestock.
Why is Fesi sponsoring such a potentially dangerous drug?
'We were misled during the COVID era, and that's where all this comes from,' Fesi said. 'As a free people, I know we can make our own decisions on what we want to do.'
Yes, but shouldn't a doctor have to prescribe a drug as dangerous as this one?
Unfortunately, Dr. Ralph Abraham, the state's surgeon general, doesn't think so. He said a lot of people are getting the drug from veterinary supply stores.
Abraham said, 'I can pretty much assure you if you asked 10 of your friends, one or two of them are probably taking ivermectin on a periodic or a daily basis.'
No surprises there since the drug has seen a surge in off-label use due to internet-fueled claims that it can treat a number of conditions or even cure cancer. The newspaper said actor Mel Gibson in January said on 'The Joe Rogan Podcast' that three friends with Stage 4 cancer got better after taking ivermectin and fenbendazole.
Why anyone would take Gibson or Rogan's medical advice is their mistake.
The drug is effective against parasites and its developers won the Nobel Prize in 2015. However, large studies have shown no significant benefit for COVID treatment, and ongoing research on its potential role in cancer remains preliminary. The Advocate said experts caution that early promise in preclinical trials rarely translates into effective therapies in humans.
OK, here are some of those experts:
Dr. Jon Mizrahi said he now fields requests for ivermectin constantly in his New Orleans practice as a cancer specialist. He said his gastrointestinal cancer patients began asking for it during the COVID-19 pandemic.
Over two weeks this spring, he said more than half of his new patients asked about the drug. Some hoped to combine it with chemotherapy. Others planned to take ivermectin instead. They had problems.
Two patients had to delay chemotherapy because ivermectin elevated their liver enzymes. One patient, newly diagnosed with late-stage cancer, wanted to try ivermectin before chemo or radiation. Two months later, that person's cancer had gotten significantly worse.
The newspaper said Mizrahi is one of dozens of cancer specialists in Louisiana raising concerns about Fesi's bill. In a letter signed by 40-plus providers and the Cancer Advocacy Group of Louisiana and Louisiana Oncology Society, opponents of the bill emphasized that standard cancer treatments such as chemotherapy, radiation, and immunotherapy are grounded in rigorous clinical trials, while ivermectin lacks research.
Dr. Mary Maluccio, a surgical oncologist specializing in rare cancers in New Orleans, said she hears about ivermectin upward of a dozen times a week. Two of her patients died of liver failure after adding ivermectin to their regimen without informing the care team. The patients had cancers requiring aggressive chemotherapy that put their livers at risk anyway — but Maluccio suspects ivermectin contributed to the swift pace of decline.
The newspaper said for many cancer patients, experimenting with holistic remedies — green tea, turmeric, smoothies — is a way to feel some control. Maluccio said she doesn't fault them for it. But ivermectin, she said, isn't just a harmless add-on.
For patients facing advanced or rare cancers, the desire to try anything can be understandable, Maluccio said. But it becomes difficult to treat cancer with proven methods if a drug without known interactions is added to the mix, or there is no protocol for how taking it might impact surgery.
It's extremely difficult to understand how 28 of Louisiana's 39 state senators voted for Fesi's bill, and four of them represent this corner of the state. I'm sticking with my physicians, not those who, like Abraham, are touting ivermectin as some kind of wonder drug.
Jim Beam, the retired editor of the American Press, has covered people and politics for more than six decades. Contact him at 337-515-8871 or jim.beam.press@gmail.com. Reply Forward
Add reaction

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Politico
12 minutes ago
- Politico
GOP lawmakers stick with Trump in messy Musk breakup
Amid the messy ongoing divorce between the president and the world's richest man, this much is already clear: Donald Trump has sole custody of the House GOP. Republican lawmakers are making clear that, if forced to choose, it's Trump — not Elon Musk — they're sticking by as leaders race to contain the fallout for their 'one big, beautiful bill.' Even Rep. Marjorie Taylor Greene of Georgia, who helms a House panel inspired by Musk's Department of Government Efficiency initiative, blasted Musk's public attacks on Trump as 'unwarranted' and criticized his 'lashing out on the internet.' 'America voted for Donald Trump on Nov. 4, 2024 — every single vote mattered just as much as the other,' Greene said in a brief interview. 'And whether it was $1 that was donated or hundreds of millions of dollars, the way I see it, everybody's the same.' Like many Americans, GOP members watched Thursday's online exchange with a sense of car-crash-like fascination. Many shared that they hoped Musk and Trump could somehow patch things up. But many — including some of the former DOGE chief's biggest backers on Capitol Hill — were wholly unsurprised to see the billionaire suddenly cut down to size after months of chatter about who was really calling the shots at the White House. 'It's President Trump, not President Musk,' said one lawmaker granted anonymity to speak frankly about prevailing opinions inside the House GOP. Speaker Mike Johnson made no secret of where he stands on the public breakup. He told reporters Friday that he hoped the two men 'reconcile' and that it would be 'good for the party and the country if all this worked out.' But in the nearly same breath, Johnson quickly reaffirmed his allegiance to the president and issued a warning to Musk. 'Do not doubt, do not second-guess and don't ever challenge the president of the United States, Donald Trump,' Johnson said. 'He is the leader of the party. He is the most consequential political figure of this generation and probably the modern era. And he's doing an excellent job for the people.' Other House Republicans concurred with the speaker's assessment Friday, even as they faced the looming threat of Musk targeting them in the upcoming midterms or at least pulling back on his political giving after pouring more than $250 million into the 2024 election on behalf of Trump and the GOP ticket. 'I think it's unfortunate,' said Rep. Tim Moore (R-N.C.) of the breakup. 'But Donald Trump was elected by a majority of the American people.' Rep. Warren Davidson of Ohio, who was one of only two Republicans to oppose Trump's megabill in the House last month, also made clear he stood with the president over Musk. 'He does not have a flight mode — he's fight, fight, fight … and he's been pretty measured,' Davidson said of Trump. 'I think Elon Musk looked a little out of control. And hopefully he gets back and grounded.' GOP leaders who have spent weeks cajoling their members to vote for the sprawling domestic-policy bill hardly hid their feelings as Musk continued to bash the legislation online, even calling on Americans to call their representatives in an effort to tank it. 'Frankly, it's united Republicans even more to go and defend the great things that are in this bill — and once it's passed and signed into law by August, September, you're going to see this economy turning around like nothing we've ever seen,' Majority Leader Steve Scalise said in a brief interview Friday. 'I'll be waiting for all those people who said the opposite to admit that they were wrong,' Scalise added. 'But I'm not expecting that to happen.' A few Republicans are still trying to walk a fine line by embracing both Trump and Musk — especially some fiscal hawks who believe Musk is right about the megabill adding trillions to the national debt. 'I think Elon has some valid points about the bill, concerns that myself and a handful of others were working to address up until the passage of it,' Rep. Michael Cloud (R-Texas) said in an interview. 'I think that'll make the bill stronger. I think it'll help our standing with the American people.' Both Trump and Musk 'have paid a tremendous price personally for this country,' Cloud added. 'And them working together is certainly far better for the country.' Notably, House Judiciary Chair Jim Jordan, a key Musk ally on the Hill, declined to engage Thursday when asked about the burgeoning feud. Instead, the Ohio Republican responded by praising the megabill Musk had moved to tank. Democrats, for their part, watched the unfolding and public breakup with surprise and a heavy dose of schadenfreude. 'There are no good guys in a fight like this,' Rep. Jared Huffman (D-Calif.). 'You just eat some popcorn and watch the show.'


The Hill
12 minutes ago
- The Hill
Freedom Caucus warns it will ‘not accept' Senate changes on green energy tax credits
The conservative House Freedom Caucus said on Friday that it would 'not accept' changes that 'water down' its cuts to green energy tax credits as the Senate weighs whether to alter the legislation. The House version of the 'big, beautiful bill' would make drastic changes to tax cuts for low-carbon energy sources passed in the Democrats' 2022 Inflation Reduction Act (IRA). Climate-friendly energy projects, including wind and solar, would only be able to qualify for the credits under the House bill if they begin construction within 60 days of the bill's enactment. This brief window would likely make many projects ineligible for the credits, and is expected to significantly hamstring the development of new renewable power. In a post on social media on Friday, the Freedom Caucus warned the Senate against loosening that restriction or others included in the bill. 'We want to be crystal clear: if the Senate attempts to water down, strip out, or walk back the hard-fought spending reductions and IRA Green New Scam rollbacks achieved in this legislation, we will not accept it,' said the post, which was attributed to the Freedom Caucus's board. 'The House Freedom Caucus Board will stand united holding the line. The American people didn't send us here to cave to the swamp — they sent us here to change it,' they added. The Senate has been widely expected to consider changes that could slow the rapid elimination of the tax credit passed under the House version of Trump's 'big beautiful bill.' Republican Sens. Lisa Murkowski (Alaska), Thom Tillis (N.C.), Jerry Moran (Kan.) and John Curtis (Utah) released a letter warning against a 'full scale' repeal of the tax credits. Senate Republicans can only afford three defections and pass their bill. On Friday, a group of 13 House GOP moderates released a letter calling on Senate leadership 'to substantively and strategically improve clean energy tax credit provisions' in the legislation. 'We believe the Senate now has a critical opportunity to restore common sense and deliver a truly pro-energy growth final bill that protects taxpayers while also unleashing the potential of U.S. energy producers, manufacturers, and workers,' said the letter, which was led by Reps. Jen Kiggans (R-Va.) and Brian Fitzpatrick (R-Pa.). Altogether, the letters illustrate what could be a tough task ahead of the Republican leadership as they look to find a measure that will keep at least 50 senators on board and appease the House. Emily Brooks contributed.


Axios
15 minutes ago
- Axios
Scoop: LaCivita signs up for Florida Senate race
Senior Trump political adviser Chris LaCivita is joining a super PAC bolstering Florida Sen. Ashley Moody in next year's midterm election, Axios has learned. Why it matters: LaCivita gives Moody, who has filled the seat formerly held by now-Secretary of State Marco Rubio, the imprimatur of support from President Trump's orbit. Moody was appointed in January to the seat by Florida Gov. Ron DeSantis, who faced off against Trump in a bitter battle for the Republican nomination in 2024. Moody, a former Florida attorney general, is seeking a full term in 2026. She has yet to attract a serious primary challenger. Zoom in: Moody has also brought on Tony Fabrizio, another chief strategist on Trump's 2024 campaign. LaCivita and Fabrizio are playing key roles in steering Trump's cash-flush political operation. LaCivita is working for several other GOP candidates running next year, including Texas Sen. John Cornyn and Michigan Senate hopeful Mike Rogers.